— Agilent Technologies (NYSE: A) reported its fourth-quarter 2019 adjusted earnings of $0.89 per share versus $0.85 per share expected.
— Revenue grew by 6% to $1.37 billion versus $1.33 billion expected.
— Life Sciences and Applied Markets Group sales rose 4% on continued strength in Environmental & Forensics markets.
— Agilent CrossLab Group grew by 8% on broad growth across major markets and regions, while Diagnostics and Genomics Group saw 5% growth aided by Pathology and Companion Dx and ongoing demand in Pharma for oligo-manufacturing.
— Looking ahead into the first quarter of 2020, the company expects revenue in the range of $1.34-1.355 billion and adjusted earnings of $0.80-0.81 per share. Analysts expect EPS of $0.84 on revenue of $1.38 billion.
— For the full year 2020, the company predicts revenue in the range of $5.50-5.55 billion and adjusted earnings of $3.38-3.43 per share. The consensus estimates EPS of $3.44 on revenue of $5.55 billion.
Biogen (NASDAQ: BIIB) reported third-quarter 2021 financial results before the regular market hours on Wednesday. The company reported Q3 revenue of $2.78 billion, down 18% year-over-year and higher than the
Verizon (NYSE: VZ) reported Third-quarter 2021 financial results before the regular trading hours on Wednesday. The telecommunications giant reported Q3 revenue of $32.9 billion, up 4.3% year-over-year and above the
Philip Morris International Inc. (NYSE: PM) reported Third-quarter 2021 earnings results today. Net revenues increased 9% year-over-year to $8.1 billion. The reported net income amounted to $2.42 billion compared to